Guidant

(GDT)

received

Food and Drug Administration

approval to market two new catheters designed to treat blocked coronary arteries.

The FDA's approval of the Powersail and the Highsail coronary dilation catheters follows the clearance by regulators in Europe and Japan.

The catheters are used to open blocked coronary vessels during a type of angioplasty. Both devices use an advanced balloon technology that allows physicians to treat harder, stenotic lesions.

Guidant, which is based in Indianapolis, makes therapeutic medical devices for treating cardiovascular and vascular diseases. The company's shares fell $1.04, or 2.1%, to $48.79 in recent

New York Stock Exchange

trading.